ClinicalTrials.gg
Status unknownNCT05720234Updated Feb 9, 2023

Avatrombopag Combined With IST as First-line Treatment for SAA

A Phase 2 interventional study of avatrombopag in Severe Aplastic Anemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Status unknown at 1 site in China. Open to participants aged 12 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-02-09.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
12 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China — 16 open to participants now, 18 under way, none of them phase 3. Anemia, Aplastic · Institute of Hematology & Blood Diseases Hospital, China.

Planned enrollment
7th of 25
53 · median 40
Started
2022
with 5 others
Phase 2
14 of 31
5 open now
Registered
11th of 31
by date

Among the 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China, this one is the 7th largest by planned enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2022, is one of 14 in phase 2, and was the 11th registered.

Anemia, Aplastic

373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

16 of the 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.

This study: 12 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China, or all of them as a file.
02

Study summary

This single-center study aims to evaluate the early efficacy and safety of avatrombopag combined with immunosuppressive therapy (IST) in the first-line treatment of severe aplastic anemia (SAA).

Read the detailed description

This is a single center, single arm, phase II clinical study. Fifty-three patients will be enrolled.

Treatment protocol is as follows: 1) Anti-human thymocyte porcine immunoglobulin (P-ATG 20mg/kg/d) or rabbit anti human thymocyte globulin (R-ATG 3.0mg/kg/d) was administered intravenously for 5 days; 2) Cyclosporine (CSA) is given at 3-5 mg/kg.d in divided doses for at least 6 months. The trough concentration is maintained at 150-250 ng/ml. 3) Avatrombopag is given orally at 60 mg once a day for patients with body weight ≥ 50 kg, and 40 mg orally once a day for patients with body weight\<50 kg, for a total of 12 weeks.

03

Conditions studied

  • Severe Aplastic Anemia

Browse trials for

Keywords

  • avatrombopag
04

Who can participate

Ages eligible
12 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with newly diagnosed severe aplastic anemia.
  2. Men and women aged between 12 and 60.
  3. Subjects must complete all screening assessments as outlined in the test protocol.
  4. Able to swallow or administer orally.
  5. Before the start of the research procedure, the patient or guardian should fully understand the research procedure and purpose and sign the form. If the patient's signature is not conducive to the treatment of the disease, the patient's immediate family should sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Congenital bone marrow failure (eg. Fanconi anemia).
  2. Accompanied by cytogenetic cloning changes (chromosomal karyotype and FISH detection found somatic cloning abnormalities; Simple -Y abnormality can be included in this study;) .
  3. ATG or middle/high-dose cyclophosphamide was used in the past.
  4. Previous treatment with cyclosporine or tacrolimus > 6 months.
  5. The total course of treatment with TPO receptor agonists (including thrombopoietin, eltrombopag,hetrombopag and avatrombopag) was more than 1 month.
  6. Serious infectious diseases (tuberculosis without effective control, pulmonary aspergillosis, viral infections).
  7. AIDS patients.
  8. Pregnant or breastfeeding, fertile but unwilling to take effective measures.
  9. Patients with malignant tumors who are not suitable for ATG treatment.
  10. A newly diagnosed history of cardio/cerebral vascular thrombosis within 12 months.
  11. Those who are assessed as unsuitable for inclusion by the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (estimated)

Study arms

  • Experimental
    Treatment group

    53 subjects will be enrolled with the indicated treatment dose of avatrombopag.

    Drug: avatrombopag

Interventions

  • Patients with body weight ≥50kg were given 60mg/day and patients with body weight \< 50kg were given 40mg/day for 12 weeks.

    Also known as: AVA, APAG

06

What researchers measure

Primary outcomes

  1. Treatment response

    Percentage of patients who achieves complete response(CR) at 12 weeks.

    Time frame: From the start of study treatment (Day1) to end of week 12.

Secondary outcomes

  1. Treatment response

    Percentage of patients achieving hematologic response (OR) at 12 weeks.

    Time frame: From the start of study treatment (Day1) to end of week 12.

  2. Treatment response

    Percentage of patients achieving hematologic response and complete response (OR and CR) at 24 weeks.

    Time frame: From the start of study treatment (Day1) to end of week 24.

  3. Supportive treatment

    The time of red blood cell or platelet recovery to transfusion independence.

    Time frame: From the start study treatment (Day1) up to transfusion independence.

  4. Incidence of Treatment-Emergent Adverse Events by CTCAE

    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: From the start study treatment (Day1) up to week 12.

  5. Dose-effect relationship

    Correlation between avatrombopag's serum concentration with total and complete hematological response rate.

    Time frame: From the start study treatment(Day1) up to week 24.

  6. Change of CD34+ cell

    Change of CD34+ cells' proportion in bone marrow before and after avatrombopag treatment at week 12 and 24.

    Time frame: From the start study treatment(Day1) up to end of week 12 and 24.

07

Study locations

1 of 1 sites recruiting
  • Institute of Hematology & Blood Diseases Hospital
    Tianjin, Tianjin 300020, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Nov 2023, 12 months after the start.

Of 51 non-industry phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 111. This study's planned 12 months is below that.

Counting every sponsor, half of 59 studies reached it within 76 months; a quarter within 39 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2023
First posted
Feb 9, 2023
StartActual
Nov 10, 2022
Primary completionEst.
Nov 30, 2023
CompletionEst.
Nov 30, 2024
Last update
Feb 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05720234
Responsible party
Sponsor
First posted
Feb 9, 2023
Start date
Nov 10, 2022
Primary completion
Nov 30, 2023 (estimated)
Completion
Nov 30, 2024 (estimated)
Last update
Feb 9, 2023

Study contacts

Xin Zhao, M.D
Contact
zhaoxin@ihcams.ac.cn
8613702041366
Xin Zhao
principal investigator · Institute of Hematology & Blood Diseases Hospital, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avatrombopag

Start the discussion